AstraZeneca | Cafepharma Message Boards | Pharma Sales, Device …
Mar 5, 2026 · Anonymous board for AstraZeneca. Promote your message to our pharma audience. Board-level targeting available.
AstraZeneca | Cafepharma
Apr 2, 2026 · AstraZeneca has reported positive results from the efzimfotase alfa Phase III clinical trial programme for hypophosphatasia (HPP), a rare metabolic bone disorder. The global programme …
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Anonymous discussion boards for pharmaceutical sales, medical/device sales, lab/diagnostics sales
January 14 2026 - JPM26: AstraZeneca's $80B revenue target 'very …
Jan 14, 2026 · Confidence is on full display at JPM, as companies talk up revenue targets, pipeline momentum, and dealmaking strength—tempered by ongoing regulatory and pricing realities.JPM26: …
July 24 2025 - AstraZeneca drug acquired in Alexion deal succeeds in ...
Jul 24, 2025 · AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trialAstraZeneca boardPharma giant Roche sees income soar in first halfRoche boardNovartis to pay …
AstraZeneca reports positive data from Phase III trial of efzimfotase ...
Apr 2, 2026 · AstraZeneca has reported positive results from the efzimfotase alfa Phase III clinical trial programme for hypophosphatasia (HPP), a rare metabolic bone disorder. The global programme …
September 26 2025 - Roche, Novartis underline U.S. plans after Trump ...
Sep 26, 2025 · Roche, Novartis underline U.S. plans after Trump pharma tariff announcement Roche board, Novartis board AstraZeneca joins the DTC platform pack, offering up to 70% discounts on …
AstraZeneca’s novel COPD drug secures double win in Phase III
Mar 27, 2026 · AstraZeneca’s first-in-class biologic, tozorakimab, has posted a double Phase III win in chronic obstructive pulmonary disease (COPD), which analysts say could position the drug to …
Cafepharma News
Latest news and updates on pharmaceutical and medical sales, including breakthrough treatments and industry trends.
January 26 2026 - Biopharma layoffs surged last year, but 2026 is a ...
Jan 26, 2026 · Signs of renewed momentum are emerging across the sector, as companies balance the legacy of layoffs and restructuring with clinical progress, IPO hopes, and growing use of …